Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-06-16 EDT			5-day change	1st Jan Change
498.10 ^DKK	-3.51%		+1.58%	-20.20%

06-16	Lilly will offer higher doses of Zepbound on its website	RE
06-16	European shares snap five-day losing streak	RE

Novo Nordisk Says No Meeting Scheduled With US Senate Aides, Senior Executives

Published on 2024-07-15 at 10:28, updated on 2024-07-15 at 11:31

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novo Nordisk A/S

Lilly will offer higher doses of Zepbound on its website	06-16	RE
European shares snap five-day losing streak	06-16	RE
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06-16	MT
Lilly to offer highest doses of weight-loss drug Zepbound on website	06-16	RE
NOVO NORDISK : Gets a Buy rating from JP Morgan	06-16	ZD
JP Morgan lowers target price for Novo Nordisk to 650 Danish kroner (1,000), reiterates overweight rating - BN	06-16	FW
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	06-13	RE
Global markets live: Tesla, Google, Apple, Novo Nordisk, Boeing…	06-13
Odin Norden rose 3.16 percent in May – positive reporting season for portfolio companies	06-13	FW
NOVO NORDISK : Receives a Buy rating from UBS	06-13	ZD
Novo Nordisk Surpasses SAP to Regain Europe's Most Valuable Listed Company Title	06-13	MT
Novo Nordisk regains crown as Europe's most valuable company	06-13	RE
Novo Nordisk regains crown as Europe's most valuable company	06-13	RE
Novo Nordisk is once again the highest valued listed company in Europe.	06-13	FW
Novo Nordisk: amycretin progresses to Phase 3	06-13	CF
SEB Sweden Equity Fund increased by 2.8 percent in May – divested its holding in Vitrolife	06-13	FW
Novo Nordisk takes amycretin for overweight into phase 3	06-13	FW
Novo Nordisk to Launch Late-stage Development of Amycretin Weight Management Treatment	06-12	MT
Sector Update: Health Care Stocks Higher Late Afternoon	06-12	MT
Sector Update: Health Care	06-12	MT
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year	06-12	RE
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year	06-12	RE
Novo Nordisk Plans Phase 3 Clinical Development of Amycretin for Weight Management	06-12	MT
Novo Nordisk plans to start late-stage trials for experimental obesity drug amycretin	06-12	RE
Novo Nordisk Says Planning To Initiate A Phase 3 Development Programme With Amycretin For Adults With Overweight Or Obesity During Q1 Of 2026	06-12	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

06-20 - American Diabetes Association Scientific Conference - Oral Presentation: 86-OR

More about the company